Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneus Ltd. ( (AU:CMB) ) just unveiled an update.
Cambium Bio Limited has made significant progress in its Phase 3 trials for Elate Ocular®, a treatment for dry eye disease, with ethics approvals obtained in both Australia and the United States. The company is preparing for patient dosing after satisfying FDA requirements and has secured additional funding to support its clinical operations. The financial report highlights a disciplined approach to managing costs, with a focus on research and development, while maintaining a conservative cash balance to achieve near-term milestones.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company focusing on developing innovative biologics for ophthalmology and tissue repair applications.
Average Trading Volume: 10,284
Technical Sentiment Signal: Sell
Current Market Cap: A$5.85M
For an in-depth examination of CMB stock, go to TipRanks’ Overview page.